• A lawsuit, filed today in federal court, challenges a nationwide pattern of deceptive advertising which confuses consumers by using outdated studies to compare the highest injectable doses of Lilly’s medicines against lower doses of Novo Nordisk’s injectable medicines for obesity and type 2 diabetes
  • These high-profile US advertising campaigns create the misleading impression that Lilly’s medicines are superior, including by withholding critical scientific evidence about newer, more effective FDA-approved options, such as the 7.2 mg dose of Wegovy® (semaglutide), which showed an average weight loss of 19% (~47 pounds)
  • People deserve evidence-based, up-to-date information they can trust when making decisions about their health. Novo Nordisk has taken this step because Americans should not be denied the full picture of their treatment options